Thus, targeting Hx and Hp levels, vascular endothelial TLR4 inhibition, and reducing elevated levels of sMD2 can result in promising strategies in SCD treatment and other hemolytic conditions. The gene discussed is HP; the disease is Schnyder corneal dystrophy.